...
首页> 外文期刊>International journal of clinical practice >Autologous stem cell therapy in the treatment of limb ischaemia induced chronic tissue ulcers of diabetic foot patients
【24h】

Autologous stem cell therapy in the treatment of limb ischaemia induced chronic tissue ulcers of diabetic foot patients

机译:自体干细胞疗法治疗肢体缺血引起的糖尿病足患者慢性组织溃疡

获取原文
获取原文并翻译 | 示例
           

摘要

Background and aim: Despite improvements in surgical revascularisation, limitations like anatomical factors or atherosclerosis limit the success of revascularisation in diabetic patients with critical limb ischaemia. Stem cells were shown to improve microcirculation in published studies. The aim of this study was to evaluate safety, feasibility and efficacy of transplantation of bone marrow derived cellular products regarding improvement in microcirculation and lowering of amputation rate. Methods: Bone marrow mononuclear cells (BMCs) in comparison with expanded bone marrow cells enriched in CD90+ cells ('tissue repair cells', TRCs) were used in the treatment of diabetic ulcers to induce revascularisation. Diabetic foot patients with critical limb ischaemia without option for surgical or interventional revascularisation were eligible. Parameters examined were ABI, TcPO 2, reactive hyperaemia and angiographic imaging before and after therapy. Results: Of 30 patients included in this trial, 24 were randomised to receive either BMCs or TRCs. The high number of drop-outs in the control group (4 of 6) led to exclusion from evaluation. A total of 22 patients entered treatment; one patient in the TRC group and two in the BMC group did not show wound healing during follow up, one patient in each treatment group died before reaching the end of the study; one after having achieved wound healing (BMC group), the other one without having achieved wound healing (TRC group). Thus, 18 patients showed wound healing after 45 weeks. The total number of applicated cells was 3.8 times lower in the TRC group, but TRC patients received significantly higher amounts of CD90+ cells. Improvement in microvascularisation was detected in some, but not all patients by angiography, TcPO 2 improved significantly compared with baseline in both therapy groups. Conclusion: The transplantation of BMCs as well as TRCs proved to be safe and feasible. Improvements of microcirculation and complete wound healing were observed in the transplant groups.
机译:背景与目的:尽管外科血管重建术有所改善,但诸如解剖学因素或动脉粥样硬化的局限性限制了严重肢体缺血的糖尿病患者血管重建术的成功。在发表的研究中,干细胞被证明可以改善微循环。这项研究的目的是评估在改善微循环和降低截肢率方面骨髓来源的细胞产品的安全性,可行性和有效性。方法:与富含CD90 +细胞(“组织修复细胞”,TRC)的扩增骨髓细胞相比,将骨髓单个核细胞(BMC)用于治疗糖尿病性溃疡,以诱导血运重建。患有严重肢体缺血的糖尿病足患者无需进行手术或介入性血运重建就可以入选。治疗前后检查的参数为ABI,TcPO 2,反应性充血和血管造影。结果:在该试验的30名患者中,有24名被随机分配接受BMC或TRC。对照组中的高辍学人数(6个中的4个)导致被排除在评估之外。共有22例患者进入治疗; TRC组中的一名患者和BMC组中的两名患者在随访期间未显示伤口愈合,每个治疗组中的一名患者在研究结束前死亡。一个在伤口愈合后(BMC组),另一个在伤口愈合后(TRC组)。因此,有18位患者在45周后显示伤口愈合。 TRC组中的总应用细胞数比传统方法少了3.8倍,但TRC患者的CD90 +细胞数量明显增加。通过血管造影检测到部分但并非所有患者的微血管形成均得到改善,两个治疗组的TcPO 2均较基线显着改善。结论:BMCs和TRCs的移植是安全可行的。在移植组中观察到微循环的改善和伤口完全愈合。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号